For research use only. Not for therapeutic Use.
BML-190 (CAT: I002971), also known as IMMA, emerges as a potent and selective ligand for the cannabinoid receptor type 2 (CB2). This compound’s interaction with CB2 receptors highlights its significance in the endocannabinoid system, which plays a crucial role in various physiological processes, including immune regulation, inflammation, and pain modulation. BML-190’s selectivity for CB2 receptors suggests its potential application in pharmaceutical research for developing targeted therapies that harness the CB2 pathway for managing immune-related disorders and inflammatory conditions.
| Catalog Number | I002971 |
| CAS Number | 2854-32-2 |
| Synonyms | 2-[1-(4-chlorobenzoyl)-5-methoxy-2-methylindol-3-yl]-1-morpholin-4-ylethanone |
| Molecular Formula | C23H23ClN2O4 |
| Purity | ≥95% |
| Target | Neuronal Signaling |
| Solubility | 10 mM in DMSO |
| Storage | 3 years -20C powder |
| IC50 | 435 nM(Ki CB2) |
| InChIKey | BJSDNVVWJYDOLK-UHFFFAOYSA-N |
| Reference | </br>1:In vitro metabolism of indomethacin morpholinylamide (BML-190), an inverse agonist for the peripheral cannabinoid receptor (CB(2)) in rat liver microsomes. Zhang Q, Ma P, Cole RB, Wang G.Eur J Pharm Sci. 2010 Sep 11;41(1):163-72. doi: 10.1016/j.ejps.2010.06.004. Epub 2010 Jun 11. PMID: 20542112 Free PMC Article</br>2:BML-190 and AM251 act as inverse agonists at the human cannabinoid CB2 receptor: signalling via cAMP and inositol phosphates. New DC, Wong YH.FEBS Lett. 2003 Feb 11;536(1-3):157-60. PMID: 12586356 Free Article |
